Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

ARTAÇ, MEHMET; COŞKUN, HASAN; Korkmaz, Levent; Kocer, Murat; Turhal, Nazim; ENGİN, HÜSEYİN; Dede, Isa; PAYDAŞ, SEMRA; Oksuzoglu, Berna; Bozcuk, Hakan; DEMİRKAZIK, AHMET

doi:10.1016/j.clgc.2016.04.021

Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Copy For Citation

ARTAÇ M., COŞKUN H. Ş., Korkmaz L., Kocer M., Turhal N. S., ENGİN H., ...More

CLINICAL GENITOURINARY CANCER, vol.14, no.4, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 14 Issue: 4
Publication Date: 2016
Doi Number: 10.1016/j.clgc.2016.04.021
Journal Name: CLINICAL GENITOURINARY CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Keywords: Cytokine therapy, VEGF inhibitors, Progression free survival, Sorafenib, Sunitinib, ENDOTHELIAL GROWTH-FACTOR, SUNITINIB, INTERLEUKIN-2, THERAPY, SU11248
Çukurova University Affiliated: Yes

Abstract

Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.